Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04918173 · ClinicalTrials.gov registry record · Phase 3
Efficacy of Atenativ in Patients With Congenital Antithrombin Deficiency Undergoing Surgery or Delivery
A Phase 3 study of Congenital Antithrombin Deficiency, sponsored by Octapharma.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 38
- Enrollment target
- 20
- Study locations
NCT04918173 is a Phase 3 study of Congenital Antithrombin Deficiency that is actively recruiting participants, run by Octapharma. The registered enrollment target is 38 participants. The trial reports 20 study locations across 6 states.
The verdict
NCT04918173, a Phase 3 study of Congenital Antithrombin Deficiency, is actively recruiting participants, sponsored by Octapharma.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 38 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this study is to assess the incidence of the composite of thrombotic events (TEs) and thromboembolic events (TEEs) in patients with congenital antithrombin deficiency under when they receive Atenativ for surgical procedures or parturition.
Conditions Studied
Interventions
- DRUG Atenativ
Study Locations (20)
Other
- Yeolyan Hematology and Oncology Centre - Yerevan
- Universitätsklinik für Innere Medizin Klinische Abteilung für Hämatologie und Hämostaseologie - Vienna
- Centre for Thrombosis and Haemaostasis - Nymburk
- Centre de Référence de l'Hémophilie Unité d'Hémostase Clinique Hôpital Cardiologique Louis Pradel - Bron
- University Hospital of Reims - Reims
- Centre Hospitalier Universitaire de Rouen (CHU de Rouen) - Centre de Traitement des Maladies Hemorragiques (CRTH) (Centre d'Hemophiles) - Rouen
- Aversi Clinic - Tbilisi
- Klinik fur Angiologie Hamostaseologie Haus 12 A Gerinnungssprechstunde - Berlin
- UKB Bonn Institut für Experimentelle Hämatologie und Transfusionsmedizin - Bonn
- Gerinnungszentrum Rhein-Ruhr - Duisburg
- University of Debrecen, Medical and Health Science Centre - Debrecen
- Rabin Medical Centre, Institute of Haematology - Petah Tikva
- Sheba Medical Centre - Ramat Gan
- Unita Strutturale Complessa di Immunoematologia e Medicina Trasfusionale -Dipartimento Interaziendale di Medicina Trasfusionale ed Ematologia - ASST Papa Giovanni XXIII ematologia Piazza OMS, 1 - Bergamo
- Universita degli Studi di Milano - IRCCS Ospedale Maggiore Policlinico - Centro Emofilia e Trombosi Angelo Bianchi Bonomi - Milan
District of Columbia
- Georgetown University - Washington D.C.
Florida
- University of Miami - Miami
Illinois
- Bleeding and Clotting Disorders Institute - Peoria
New York
- Weill Cornell Medicine - New York
North Carolina
- Duke University - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2022-07-01 |
| Est. Completion | 2026-06-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04918173
The ClinicalTrials.gov registry entry for NCT04918173 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Octapharma, which has 43 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Congenital Antithrombin Deficiency appearing as the primary indexed condition, and to 1 intervention - of which Atenativ is the first listed.
NCT04918173 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Other, District of Columbia, Florida.
Frequently Asked Questions
What is clinical trial NCT04918173 about?
NCT04918173 is a clinical study titled "Efficacy of Atenativ in Patients With Congenital Antithrombin Deficiency Undergoing Surgery or Delivery". The goal of this study is to assess the incidence of the composite of thrombotic events (TEs) and thromboembolic events (TEEs) in patients with congenital antithrombin deficiency under when they receive Atenativ for surgical procedures or parturition.
What is the current status of trial NCT04918173?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 38 participants. The study started on 2022-07-01. Estimated completion is 2026-06-01.
What conditions does trial NCT04918173 study?
This clinical trial studies the following conditions: Congenital Antithrombin Deficiency.
What interventions are being tested in trial NCT04918173?
The interventions under investigation include: Atenativ (DRUG).
Who is sponsoring clinical trial NCT04918173?
This trial is sponsored by Octapharma, which has 43 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04918173 being conducted?
This trial has 20 study locations across District of Columbia, Florida, Illinois, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.